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Abstract

Dementias are clinical neurodegenerative diseases characterized by permanent and
progressive transformation of cognitive functions such as memory, learning capacity,
attention, thinking, language, passing judgments, calculation or orientation. Dementias
represent a relatively frequent pathology, encountered at about 10% of the population of 65year olds and 20% of the population of 80-year olds.
This review presents the main etiological forms of dementia, which include Alzheimer
form of dementia, vascular dementia, dementia associated with alpha-synucleionopathies, and
mixed forms. Regarding vascular dementia, the risk factors are similar to those for an
ischemic or hemorrhagic cerebrovascular accident: arterial hypertension, diabetes mellitus,
dyslipidemia, smoking, obesity, age, alcohol consumption, cerebral atherosclerosis/
arteriosclerosis.
Several studies show that efficient management of the vascular risk factors can prevent the
expression and/ or progression of dementia. Thus, lifestyle changes such as stress reduction,
regular physical exercise, decreasing dietary fat, multivitamin supplementation, adequate
control of blood pressure and serum cholesterol, and social integration and mental stimulation
in the elderly population are important factors in preventing or limiting the symptoms of
dementia, a disease with significant individual, social, and economic implications.
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Highlights:

✓ Dementia is a neurocognitive disorder with multiple and severe (individual, social, and
economic) implications.
✓ Lifestyle changes implying stress reduction, regular physical exercise, decreasing
dietary fat, social integration and mental stimulation in the elderly population are
important factors in preventing or limiting the symptoms of dementia
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due to another medical condition, NCD due to multiple

Introduction
Neuro-cognitive
disorders
(NCD)
are
neurodegenerative diseases characterized clinically by
persistent and progressive impairment of cognitive
functions (1). These impairments are usually inherited,
with etiology and pathogeny currently documented, but
they are not considered developmental disorders (2).
According to the American Psychiatric Association
and The Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM5), the term dementia was
replaced with the notion of major neurocognitive
disorder (NCD), defining thus a broad spectrum of
cognitive and functional disorders that form the basis for
diagnostic criteria. Nevertheless, for certain etiological
subtypes, the term of dementia is standard (2). Thus,
according to the current international agreement, for the
confirmation of a major neurocognitive disorder, the
cognitive deficiency and the main clinical SDR (source
data review) must be characterized by a significant
decline in performance compared to a previous level in
one or more cognitive fields such as: memory, learning,
complex attention, executive function, perceptual-motor
skills related to language skills, or social knowledge. The
cognitive deficiency must interfere with daily activities,
and the health care provider might request evidence of
minimum assistance for daily routines (e.g., invoices,
payment, testimonials from relatives, etc.). At the same
time, the cognitive deficiency must not be associated
with a psychological disorder, such as a major depression
or schizophrenia. (3).
This paper presents the main etiological forms of
dementia, focusing discussion especially on vascular
neurocognitive disorder and the vascular risk factors
implicated

(diabetes

mellitus,

age

and

arterial

hypertension, the metabolic syndrome, smoking and
alcohol consumption), as a premise to further understand
and develop therapeutic and prophylactic guidance
related to this severe disease.

Discussion
DSM5 defines the incipient stage of dementia when
the cognitive disorder is less severe as a minor
neurocognitive disorder. Several diagnostic criteria are
also formulated for this incipient stage. The subtypes of
minor or major NCD are: NCD due to Alzheimerʼs
disease, vascular NCD, NCD with Lewy bodies, NCD
due to Parkinsonʼs disease, frontotemporal NCD, NCD
due to traumatic brain injury, NCD due to HIV infection,
substance/ medication-induced NCD, NCD due to
Huntingtonʼs disease, NCD due to prion disease, NCD

etiologies, and unspecified NCD (1, 2).
Regarding their global prevalence, dementias, a term
almost super-imposable with major NCD, represent 12% of the population of 65 and older, and 30% by age 85
(3). Estimations of the prevalence of minor NCD for the
older patients range between 2-10% at the age 65 and 525% at the age 85 (2). The most common etiological
factors are represented by: Alzheimer disease (60%–
80%), dementia with Lewy bodies, Parkinson disease
with dementia (10%–20%), frontotemporal dementia
(5%–10%), cerebrovascular disease (10%– 20%) (4).
Vascular neurocognitive disorder is the result of
reduced cerebral blood flow that can either produce an
ischemic stroke, with different strategic localizations at
the cerebral level (such as the angular gyrus, the
temporal lobe, the frontal lobe, the thalamus, the caudate
nucleus, the hippocampus), or result in modifications
such as the hyaline and fibrosis of the small vessels with
the appearance of infarcts at the level of the cerebral
white matter (clinically silent or accompanied by
neurological non-specific signs). These injuries of the
white matter generate interruptions of the cortical and
subcortical circuits, with the deterioration of complex
attention, information processing speed, and executive
skills and abilities, resulting in a neurocognitive disorder
(5-7). At the same time, there are also the so-called
cortical– subcortical border zone infarcts, the result of
hypoperfusion from atherosclerosis, as well as extended
episodes of arterial hypotension that can be accompanied
by NCD. Consequently, neurocognitive disorders having
as etiology the cerebrovascular diseases actually
represent a vast group of manifestations from the
cognitive vascular sphere. They are characterized by two
subcategories: medium or major NCD (7).
The major vascular NCD represents the second most
frequent cause of NCD, second only to Alzheimer
disease. In the USA, the prevalence of vascular dementia
is 0,2% for those between 65-70 years, and more than
16% for those over 80. In the first three months after a
stroke, about 20-30% of the patients are diagnosed with
dementia. Regarding patients with neurological
pathology, the prevalence of vascular dementia increases
from 13% at age 70 to 44,6% at age 90, compared to the
Alzheimer disease (23,6%-51%), and to vascular
dementia associated with the Alzheimer disease (2% 46,4%). The prevalence is higher for men and AfroAmericans, compared to Caucasians and East Asians (2,
3).
The revised NINDS-AIRENS criteria (National
Institute of Neurological Disorders and StrokeAssociation Internationale pour la Recherche et
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ischemic scale (8, 9) have been unanimously accepted
and used by neurologists for diagnosing vascular
dementia. Initially, dementia related to the vascular
traumas or injuries was labeled arteriosclerotic dementia,
then multi infarct dementia, post-stroke dementia, and
vascular dementia; the term currently used is vascular
cognitive disorder (7). A correct diagnosis typically
requires a fairly complicated algorithm. The DSM5
diagnostic criteria elaborated by the American
Psychiatric Association are also formulated.
The main types of the vascular neurocognitive
disorder are as follows (10):
1. Cortical vascular dementia or multi infarct dementia,
(Multi-infarct Dementia), characterized by the presence
of infarcts in the cortical and subcortical regions of the
cerebral arteries and clinically by the existence of motor
deficits, unilateral sensitivity disorders, and the gross
occurrence of cognitive decline and aphasia.
2. Subcortical vascular dementia or the dementia of
small bloood vessels, (Subcortical Ischemic Vascular
Dementia or Bisswangerʼs Disease), a condition of
cerebral insufficiency and Bisswangerʼs disease,
clinically characterized by pure motor deficits, signs of
bulbar palsy, dysarthria emotional lability, or deficits of
executive functions.
3. Cortical and subcortical vascular dementia, (Mixed
Dementia) with mixed components.
4. Strategic infarction dementia involving the strategical
spheres of the brain such as the thalamus, hippocampus,
fronto-cingulate cortex, temporal lobe-median area, and
basal portion of the brain (1, 7-9).
5. Other types of vascular dementia are: vasculits,
cerebral amyloid angiopathy (CAA), and hereditary
disease such as CADASIL (Cerebral Autosomal
Dominant Arteriopathy with Subcortical Infarcts And
Leukoencefalopathy).
The last type is an hereditary affectation with
autosomal transmission (mutations of the Notch3 gene
from the 19 chromosome that codifies a dominant
transmembrane receptor that is to be found in the
vascular flat muscle and at the level of the pericytes, in
the case of the adults) that is rarely encountered. It is
clinically associated with: progressive dementia, mood
disorders, migraine with aura, and recurrent subcortical
cerebral infarctions (10, 11). The cerebral amyloid
angiopathy (CAA) affects persons over 65, and shows an
increased incidence for those 80-90 years old.
Other types of vascular neurocognitive disorder are
(7):
1. Post-ischemic encephalopathy that is divided into 3
subentities:

o the cortical laminar necrosis, localized in the areas
of arterial border associated with the diffuse deterioration
of white matter;
o multiple post-ischemic injuries that have as a
substratum the hypotension and enlargement of the
vascular wall with the reduction of the cerebral blood
flow and the generation of minor cortical and subcortical
infarctions;
o hippocampal sclerosis characterized at the
neuropathological level by neuronal loss and gliosis,
noticed in patients over 85 years olds who were not
previously affected by the Alzheimerʼs dementia, but
with pathological antecedents of cardiac insufficiency
and cerebral hypoperfusion.
2. Hemorrhagic dementia. Cerebral bleedings do not
regularly cause dementias. However, there may be a
connection between cerebral bleedings and NCD,
depending on its localization and/or dimension, or in the
case of cortical and subcortical hemorrhages, whether the
patient had arterial hypertension antecedents. According
to several hypotheses, several mechanisms might explain
the appearance and development of certain
neurocognitive disorders for patients affected by a
stroke, such as (5, 6, 12):
o the cerebral injuries determined by an ischemic or
hemorrhagic stroke, involving neurological deficits
(motor deficits, sensitivity, language or sight disorders,
etc.) can result in perturbations of superior nervous
functions, having as clinical expression minor or major
neurocognitive disorders;
o after an ischemic or hemorrhagic stroke, the
neurocognitive disorder may actually be a continuation
of a preexistent state, such as the Alzheimer dementia,
not made known by the patient, or not diagnosed before
the cerebrovascular event;
o the recidivated ischemic stroke can lead to the
development of the neurocognitive disorders; as is well
known, multiple ischemic attacks can favor the
development of certain cognitive disorders characterized
by a rapid progressive model (multi infarction dementia).
These hypotheses are supported by the fact that an
ischemic stroke is associated with two physiopathological mechanisms:
1. Arterial enlargement with the consecutive narrowing
of the lumen, modifications resulting from factors such
as arterial hypertension, certain diseases, dyslipidemia,
or genetic factors. These modifications are represented
by deposits of fibrinoid, the hypertrophy of the flat
musculature, and other elements of conjunctive tissue
present in the arterial wall, a phenomenon called
fibrinoid degeneration and lipohyalinosis (11).
2. Obstruction of the origins of penetrating arteries by
parent large intracranial artery intimal plaques. It has
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been noticed that these modifications of the cerebral
large blood vessels are much more important for the
determination of a stroke than the intrinsic injury of the
small blood vessels. Thus, the decrease in the blood flow
in the cerebral small arteries or their obstruction is
generated either by the existence of the atheroma plaque,
that can be situated at the level of the large cerebral
blood vessels, or by the existence of the microatheromas
that can be found precisely on the place of origin of the
small arteries. The atheroma plaque initially takes shape
by the enlargement of the main blood vessels followed
by the deposition of the lipids in the blood, the
accumulation of lipid laden macrophages, cholesterol
crystals and the deposition of calcium at the level of the
main blood vessels.
This process is accompanied by a local
inflammatory reaction that includes lymphocytes and
macrophages, with the loss of the elasticity specific to
the arterial wall, the narrowing and then the occlusion of
the arterial lumen. The atheroma plaque can break and
injure the distal cerebral arteries (11). The described
atherosclerotic mechanism can combine with the
thrombotic one, and this steno-occlusive mechanism of
the small blood vessels is favored by: the increased
resistance of the blood vessels to the blood flow, the
denatured vascular self-adjustment, the modifications of
the hematoencephalic barrier, the modifications of the
vascular endothelium, and the dilation of the perivascular
spaces (10). Thus, both minor ischemic lesions, (lacunar
strokes) with a diameter ranging between 1-15 mm and
anomalies at the cerebral white matter take place at the
level of the brain, due to the demyelination of the myelin
sheath and consequently of the axons and deterioration
of the oligodendrocytes, but without the development of
profound infarctions or cystic necrosis (10, 11).
The most frequent localizations of the lacunar
strokes are: the putamen, the pallidum, thalamus, caudate
nucleus, the internal boll and the corona radiata, the
cerebral trunk, and the cerebellar white matter. The
association between these minor strokes and
modification of the white matter represent the
Bisswanger disease (7, 11). The large number of lacunae
associated with the injuries of white matter determines
interruptions of the prefrontal-subcortical, thalamocortical, striato-cortical circuits, as well as deterioration
of the limbic system, structures that play specific roles in
cognition, memory, and behaviour, thus being
responsible for the development of the neurocognitive
disorders (7, 11). However, it seems that the
accumulation of b–amyloid and of the neurofibrillary
tangles, specific to the Alzheimer disease, can facilitate
and accelerate the development of the cerebral ischemic

lesions and then of the neurocognitive disorders (10). It
is well known that the cholinergic system plays a role in
the adjustment of the cerebral blood flow. Its dysfunction
can lead to the reduction of blood flow and thus to the
development of the cerebral hypoperfusion, representing
a risk factor for the production of the cognitive decline.
o Significant hemodynamic stenosis of the large
cerebral blood vessels affected by atherosclerosis or
arteriopathy that affects the small cerebral vessels,
reducing the cerebral blood flow, without the induction
of cerebral lesions leads to the development of a
cognitive deterioration syndrome; this mechanism is not
sufficiently investigated (3). We also note, in the context
of the injury of the cerebral microcirculation, the
existence of the incomplete ischemia and of the selective
tissue necrosis that are clinically characterized by the
cognitive decline (13, 14).
o Structural alterations of the small cerebral blood
vessels, such as arteriosclerosis, lipohyalinosis, cerebral
amyloid angiopathy CAA, CADASIL, etc., that can
determine the lacunar strokes or modifications of the
typical cerebral white matter seem to be responsible for
the development of certain cognitive disorders similar to
those related to subcortical vascular dementia (15-17). At
the level of the small blood vessels, apart from the
fibrinoid degeneration and lipohyalinosis, there is also
the possibility of accumulation of a granular material that
can infiltrate from the main blood vessels to the tunica
adventitia of the arterial wall. This aspect is specific to
the hereditary diseases such as CADASIL.
Anatomopathological studies have also revealed the
presence of glycoproteins at the level of the arterial wall,
whereas the muscle fibres present in the medium tunic
are hypertrophied, deteriorated, and the vascular
endothelium can be absent or replaced with the cholagen
(11). Devoid of the muscle layer, the vascular wall in the
CAA becomes thicker due to a hyaline, acellular
material, while the presence of A-beta peptide in persons
diagnosed with arterial hypertension increases the brainʼs
vulnerability to the ischemic lesions. It has been
demonstrated that the CAA rarely causes spontaneous
cerebral hemorrhages (7).
There are pathogenic mechanisms that explain the
development of vascular neurocognitive disorders,
namely (7): the sedimentation of the amyloid at the
brainʼs level, the existence of the subdiagnosed
Alzheimer disease, with a series of studies showing that
it can coexist with the vascular risk factors. Thus,
Alzheimer disease associated with the cerebrovascular
disease has been accepted as a diagnosis (1), the
phenomenon of growing old, atherosclerosis, the arterial
hypertension.
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These pathogenic links bring about the
cerebrovascular disease and dementia, relying on an
inflammatory-type mechanism and the oxidative stress at
the vascular level, mediated by b-amyloid and NADPH,
(Nicotinamide adenine dinucleotide phosphate) –
OXIDASE, the enzyme that represents in its turn a
permanent source of oxidative stress at the vascular
level. The cerebrovascular alterations associated with
changes in the hematoencephalic barrier increase the
brainʼs
vulnerability
to
the
hypoxic-ischemic
mechanisms, generating changes to the structure and
functions of the neurons, accelerating thus the
development of the neurocognitive disorders. Due to
their amyloidogenic role, the following etiopathogenic
factors apoE4, Ɛ2 and Ɛ3 can determine microvascular
modifications,
clinically
characteri-zed
by
neurocognitive disorders: the atrial fibrillation that via
microembolic complications induces various cognitive
declines and neurological deficits, as a result of the
microinfarcts in different areas of the brain.
Inflammation may have a role in the inducement of these
mechanisms (7).
Due to the etiopathogenic relation, the
cerebrovascular disease – neurocognitive disorders have
a multifactorial etiology, the risk factors involved in its
development being divided as follows (1, 5, 9):
o vascular: arterial hypertension, dyslipidemia,
smoking, generalized atherosclerosis, other heart
diseases, (myocardial infarction, atrial fibrillation),
smoking;
o demographic: age, education;
o genetic
o factors related to the stroke, (localization of the
lesions, the type of stroke, the type of the cerebral
lesions);
o the presence of certain factors that can lead to chronic
cerebral hypoperfusion and ischemic events, (heart
arrhythmias, heart diseases, or the congestive heart
failure, etc).

Diabetes Mellitus
Diabetes mellitus (DM) represents a major risk
factor for myocardial infarction, thromboses, and
cerebrovascular disease—ischemic or hemorrhagic
stroke, associated with mild or major vascular
neurocognitive disorders (18). The risk of developing
dementia doubles in patients diagnosed with DM who
follow antidiabetes oral drugs or Insulin treatments
compared to those without DM (19-21). Patients younger
than 65 diagnosed with diabetes mellitus are at higher the
risk of vascular dementia than older ones. The risk is
directly proportional to the duration of the disease, and it
may appear concomitantly with certain complications of

the diabetes, such as the peripheral arterial disease (2224). Various cognitive disorders can be encountered at
the level of mild or low values of glycemia (prediabetes)
(25). Jaffe and collaborators have shown in a 4-year
prospective study that older women with low blood sugar
levels have lower scores on cognitive evaluation tests
than the women with normal values (18). The second
type of DM (type II) has been associated with an
increased risk of neurocognitive disorder. This risk
increases with the increase in the number of repeated
episodes of hypoglycemia (18). Imagistic investigations
such as the cranial computed tomography (CT) scan or
magnetic resonance imaging have emphasized the
presence of cortical atrophy and a cortical or subcortical
stroke, as well as several ischemic subcortical
modifications, or leukoaraiosis in such patients. This
association is not surprising, considering the fact that
DM increases the risk of developing a stroke or lacunar
infarcts (25, 26). The association between DM type 2 and
arterial hypertension increases the risk of developing
cerebrovascular diseases. The risk decreases together
with the decrease in the values of arterial tension (18).

The age and the arterial hypertension
It is well known that advanced age (individuals over
60) is associated with both high blood pressure and
cerebrovascular disease, which in turn can lead to the
development of neurocognitive disorders (27). Knowing
that the risk of ischemic and hemorrhagic stroke accident
increases with aging leads to the conclusion that age
represents an important factor in the development of
vascular dementia. Furthermore, older patients may
develop cerebral amyloid angiopathy (CAA) that can
cause multiple cerebral infarcts, lobar hemorrhages or
microhemorrhages, and subsequent cognitive decline.
Thus, although dementia may occur at any age, older
patients are more predisposed (18). This conclusion is
consistent with epidemiological data: 2% of the
population aged from 65 to 70 are diagnosed with
dementia, 5% from 70 to 80 suffer from dementia, and
20% over 80 and 33% over 90 are diagnosed with
clinical signs of dementia (28, 29).
Blood pressure values over 160/95 mmHg represent
a major risk for the development of a vascular dementia
(23, 24). Cranial CT scans on hypertensive patients have
revealed a cortical atrophy or leukoaraiosis at the level of
the hippocampus (30, 31). High blood pressure that is not
treated or therapeutically controlled generates
dysfunctions of the cerebral vessels by modifications of
the vascular endothelium, of the flat muscle cells from
this level, and of the hematoencephalic barrier, as well as
extensive lesions at the level of the cerebral white matter
that can be associated with the cognitive decline (18, 32).
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With
endothelial
modifications
such
as
lipohyalinosis (also called the fibrinoid necrosis), a
hypertrophic remodeling and the eutrophication of the
cerebral arteries generate arterial thickening, narrowing
of the vascular lumen, stenosis, or arterial occlusion, as
well as the reduction or absence of blood flow in a
certain cerebral area, thus altering the brainʼs capacity to
adapt to an insufficient energy contribution, induced by
the reduced or absent blood flow. The mechanisms
associated with cerebral atherosclerosis in patients
diagnosed with arterial hypertension result in cerebral
ischemic lesions with different localizations and
neurocognitive disorders (33, 34). The increase in the
pressure of impulse which stands as a marker of arterial
rigidity has been associated with cognitive decline and
especially with modifications of linguistic skills and
abilities (18). Studies or clinical trials developed thus far
align with the fact that vascular dementia is less frequent
for hypertensive patients treated with hypotensors than in
untreated patients (35).

Smoking

Clinical studies have found that nicotine can
stimulate good functioning of certain neurotransmitters
involved in the generation of the different types of
dementia and especially of the Alzheimer disease, but
this relationship may be valid only in the short run. In the
long run, nicotine can modify the vascular wall,
modifying at the same time the chemical composition of
nutritive substances in the blood essential for good
functioning of brain.
Statistical studies in the USA on populations over 65
years of smokers and alcohol consumers have identified
smoking as an important risk factor for stroke and a
potential risk factor for cognitive decline (45). A Chinese
study on a large number of smokers and alcohol
consumers has demonstrated that smoking is associated
with a greater risk of developing a vascular
neurocognitive disorder. Smoking results in a
pronounced progression of the cerebral vascular lesions
as well as deterioration of the executive function a
decade later (46). Thus, smoking is a risk factor for both
The metabolic syndrome
vascular dementia and Alzheimer disease, the smokers
Metabolic syndrome is defined by the presence of at
being twice more likely to develop a certain type of
several cardiovascular risk factors: obesity, arterial
dementia (28, 29, 40).
hypertension, dyslipidemia (high TG values and low
Alcohol
values of HDL cholesterol) and DM. Metabolic
Small
quantities of alcohol may protect older
syndrome is associated with an increased risk of
developing vascular neurocognitive disorders (18), individuals against dementia and Alzheimer disease.
especially for patients aged 70 or older (18, 36, 37). At Based on several studies, 14 units of alcohol for women
the same time, for some male patients with metabolic and a maximum 21 units for men per week are not
syndrome older than 75, the cognitive decline is slightly considered excessive (a unit represents a small glass of
delayed, explained by a simple neuroprotective effect of wine or one single measure of alcoholic drinks). The
the metabolic syndrome (38). For middle-aged American Heart Association stipulates moderate alcohol
individuals, hypercholesterolemia is associated with an consumption as 1-2 portions of alcohol/day for men and
increased risk of dementia, whereas for older persons, it one portion/day for women (340g of beer, 113g of wine
is associated with a low risk of developing dementia. or 40g of alcoholic drinks); exceeding these doses
Prospective statistical studies have shown that treatment increases the risk of stroke and favors other
with statins for dyslipidemia does not influence the cardiovascular risk factors such the arterial hypertension
and obesity. Thus, moderate quantities of alcohol do not
development of neurocognitive disorders (18).
Certain studies outline the fact that the patients over eliminate the risk of developing dementia, but they can
60 with high levels of triglycerides and obesity have a play an important role in its reduction (28, 29, 40).
high risk of developing short term memory disorders and According to several large studies of chronic alcohol
even dementia (28, 39). Persons with a very high body consumers, excess alcohol is associated with the
cognitive decline of dementia (40).
mass index (BMI) are also more predisposed to
The USA study on groups over 65 years
developing dementia throughout their life (28, 40). The
demonstrated that moderate alcohol consumption
BMI effect modifies with aging (33). Studies on middlerepresents a protective factor only on the vascular
aged or older populations have shown causal
endothelium, especially for 80 years olds (45). Excessive
relationships
among
cerebrovascular
disease, alcohol consumption has neurotoxic effects on the
neurocognitive disorder, and vascular risk factors such central nervous system, thus bringing about dementia
as: hypertension (41), dyslipidemia (42), DM (43), (45). The Chinese study on a large number of smokers
associated with behavioral factors such as obesity and and alcohol consumers has shown that a daily quantity of
the lack of physical activities (44).
alcohol (beer, wine, hard liquor) is associated with a
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higher risk of vascular neurocognitive disorder than for
those who do not consume alcohol. The combination of
smoking and alcohol consumption leads to a higher risk
of developing a vascular NCD than moderate, daily
alcohol consumption or smoking (46). The triad, arterial
hypertension- smoking – DM, leads to the appearance
and development of vascular dementia (46). Although
the effects of alcohol consumption and smoking on
cognitive function have been confirmed through
numerous studies, their mechanism of action is yet
unclear (46). It has been noticed that male patients,
alcohol consumers, and carriers of the apolipoprotein E,
(ApoE) or more precisely E4 allele, who manifested
moderate cognitive disorders had rapidly-developed
dementia (46-48).
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